Intervention not reported
Dupilumab (4 RCTs; 990 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes dupilumab (4 RCTs; 990 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporin A (3 RCTs; 74 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes cyclosporin A (3 RCTs; 74 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes lebrikizumab (1 RCT; 156 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Timapiprant (1 RCT; 70 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in timapiprant (1 RCT; 70 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Total studies: 6 RCTsTotal participants: 2680 · patients with moderate to severe eczema
1 finding from 1 review
Intervention not reported
CIM331 (1 RCT; 27 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in CIM331 (1 RCT; 27 participants) (low certainty).
1 finding from 1 review
Intervention not reported
GBR830 (1 RCT; 46 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in GBR830 (1 RCT; 46 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Azathiopine (AZA) (1 RCT; 41 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in azathiopine (AZA) (1 RCT; 41 participants) (low certainty).
1 finding from 1 review
Intervention not reported
QAW039 (1 RCT; 76 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes QAW039 (1 RCT; 76 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
CsAI (1 RCT; 40 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes csAI (1 RCT; 40 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Dupilumab (5 RCTs; 1997 participants) · patients with moderate to severe eczema
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 17 RCTsTotal participants: 3972 · patients with moderate to severe eczema
1 finding from 1 review
Intervention not reported
QAW039 (1 RCT; 76 participants) · patients with moderate to severe eczema
The intervention probably leads to lower QAW039 (1 RCT; 76 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Dupilumab (9 RCTs; 1663 participants) · patients with moderate to severe eczema
The intervention may leads to lower dupilumab (9 RCTs; 1663 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Timapiprant (1 RCT; 70 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in timapiprant (1 RCT; 70 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Clinical Global (CIBIC+) · Alzheimer's disease (AD), moderate‐to‐severe
1 finding from 1 review
Intervention not reported
Clinical Global: (CIBIC+) · vascular dementia, mild‐to‐moderate severity
1 finding from 1 review
Intervention not reported
Cognitive function: ADAS‐Cog 70‐point scale · vascular dementia, mild‐to‐moderate severity
1 finding from 1 review